Abstract 3042: Inhibition of <i>de novo</i> purine biosynthesis via PPAT targeting by cucurbitacin B restrains esophageal squamous cell carcinoma growth

Abstract Background: The de novo purine biosynthesis (DNPB) pathway plays a critical role in the malignant progression of tumors. However, its specific contribution to esophageal squamous cell carcinoma (ESCC) growth, radioresistance, and response to targeted therapies remains poorly understood. Methods: In this study, the underlying metabolic change of ESCC were analyzed by untargeted metabolomics and single-cell RNA sequencing data analyses. The expression and function of PPAT were further evaluated through immunohistochemistry (IHC) and lentivirus-mediated gene manipulation. Additionally, patient-derived xenograft (PDX) and cell-derived xenograft (CDX) models were utilized to assess the role of PPAT and its inhibitor in ESCC tumor growth and radioresistance. Results: In this study, we identified phosphoribosyl pyrophosphate amidotransferase (PPAT), a key rate-limiting enzyme in the DNPB pathway, as a critical modulator of ESCC malignancy. We demonstrated that PPAT promotes the production of energy-related nucleotides, including AMP, GMP, ADP, GDP, ATP, and GTP, thereby fueling ESCC tumor growth in vitro and in vivo. Moreover, we found that Cucurbitacin B (CuB) specifically targets PPAT and induces its polyubiquitin-mediated degradation via the E3 ligase TRIM38, leading to suppression of the DNPB pathway and inhibition of tumor growth. Importantly, CuB also functions as a radiosensitizer, significantly enhancing the therapeutic efficacy of radiotherapy in ESCC. Conclusions: Our findings reveal that targeting PPAT represents a promising therapeutic strategy to suppress ESCC progression and enhance the efficacy of radiotherapy. Citation Format: Mengqiu Song, Jing Guo, Huajie Jia, Jie Tian, Pan Li, Zigang Dong. Inhibition of de novo purine biosynthesis via PPAT targeting by cucurbitacin B restrains esophageal squamous cell carcinoma growth [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3042.